• Mashup Score: 1

    The FDA and U.S. Centers for Disease Control and Prevention (CDC) are recommending that U.S. states pause their administration of Johnson & Johnson’s Janssen COVID-19 Vaccine Candidate while they review six reported cases of patients developing what they termed rare and severe blood clots after receiving the vaccine.

    Tweet Tweets with this article
    • FDA, CDC Urge Pause in J&J COVID-19 Vaccination, Citing "Rare" Blood Clots “Right now, these adverse events appear to be extremely rare. #COVID19 vaccine safety is a top priority for the federal government..." Read more: https://t.co/R4hU30VHSI #johnsonandjohnson https://t.co/vORemSrN1I

  • Mashup Score: 0

    The FDA and U.S. Centers for Disease Control and Prevention (CDC) are recommending that U.S. states pause their administration of Johnson & Johnson’s Janssen COVID-19 Vaccine Candidate while they review six reported cases of patients developing what they termed rare and severe blood clots after receiving the vaccine.

    Tweet Tweets with this article
    • FDA, CDC Urge Pause in J&J #COVID19 Vaccination, Citing "Rare" Blood Clots They are reviewing 6 reported cases of patients developing what they termed rare and severe blood clots after receiving the #vaccine. Learn more: https://t.co/R4hU30VHSI #JohnsonandJohnson